Montelukast as an Add-On Therapy to Inhaled Corticosteroids in the Treatment of Severe Asthma in Elderly Patients
Authors:
- 19 April 2012
- journal article
- clinical trial
- Published by Taylor & Francis in Journal of Asthma
- Vol. 49 (5) , 530-534
Abstract
Background. Severe asthma remains a worldwide medical problem. However, this disease has not been adequately explored in the elderly. This study was performed to determine how the addition of montelukast to antiasthmatic therapy improves the control of severe asthma in elderly patients. Methods. Elderly patients (>60 years old) with diagnoses of severe asthma were observed over 24 months of therapy: the first 12 months using inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) and the second 12 months with oral montelukast added in two-thirds of the patients, with the remaining third representing the control group. The primary efficacy endpoint of the study was the percentage of days without asthma symptoms in the first 12 months of treatment compared with the percentage after adding montelukast therapy. Results. A total of 512 elderly, asthmatic patients were included in the study: seventy-one (13.9%) patients had well-controlled asthma, 211 (41.2%) had partly controlled asthma, and 230 (44.9%) had uncontrolled asthma. During the first year of treatment using ICS and LABA, an increase in the median percentage of days without asthma was observed from 50.1% to 62.1%, as well as a decrease in the percentage of days with short beta-receptor agonist use, from 52.2% to 46.8%. These differences were significantly greater after 12 months, when montelukast was added to the therapy (78.4% and 39.5%, respectively). This improvement was not observed in the control group. After 2 years of observation, the median number of asthma exacerbation incidents per patient decreased from 1.6 per year to 1.2 per year when montelukast was added. Conclusion. Severe asthma in elderly patients is very poorly treated, with this population exhibiting very low compliance with antiasthmatic therapy. Adding montelukast provides benefits and improved control; however, it does not resolve severe asthma control problems.Keywords
This publication has 13 references indexed in Scilit:
- Improved activity and mental function related to proper antiasthmatic treatment in elderly patients with Alzheimer's diseaseAllergy and Asthma Proceedings, 2011
- A subgroup analysis of the MONICA study: A 12-month, open-label study of add-on montelukast treatment in asthma patientsJournal of Asthma, 2010
- Asthma in older adultsThe Lancet, 2010
- Adherence to Asthma Therapy in Elderly PatientsJournal of Asthma, 2010
- Diagnosis and Management of Asthma in Older AdultsJournal of the American Geriatrics Society, 2009
- Severe Asthma Patients in Korea Overestimate Their Adherence to Inhaled CorticosteroidsJournal of Asthma, 2009
- Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic reviewThorax, 2008
- Montelukast, Compared With Fluticasone, for Control of Asthma Among 6- to 14-Year-Old Patients With Mild Asthma: The MOSAIC StudyPediatrics, 2005
- Effects of montelukast and beclomethasone on airway function and asthma controlJournal of Allergy and Clinical Immunology, 2002
- Underdiagnosis of asthma in the elderlyRespiratory Medicine, 1987